Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019.
Dave Singh,Alvar Agusti,Antonio Anzueto,Peter J. Barnes,Jean Bourbeau,Bartolome R. Celli,Gerard J. Criner,Peter Frith,David M.G. Halpin,MeiLan K. Han,M. Victorina López Varela,Fernando J. Martinez,Maria Montes de Oca,Alberto Papi,Ian D. Pavord,Nicolas Roche,Don D. Sin,Robert A. Stockley,Jørgen Vestbo,Jadwiga A. Wedzicha,Claus Vogelmeier +20 more
TLDR
Blood eosinophils are recommended as a biomarker to support clinical decisions regarding the use of inhaled corticosteroids in chronic obstructive pulmonary disease patients, based on recent evidence from clinical trials.Abstract:
Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic and biological information in order to optimise the therapeutic benefit relative to the possibility of side-effects for each individual. Recent clinical trials have shown that higher blood eosinophil counts are associated with a greater efficacy of inhaled corticosteroids (ICSs) in chronic obstructive pulmonary disease (COPD) patients. Blood eosinophil counts are a biomarker with potential to be used in clinical practice, to help target ICS treatment with more precision in COPD patients with a history of exacerbations despite appropriate bronchodilator treatment. The Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 pharmacological treatment algorithms, based on the ABCD assessment, can be applied relatively easily to treatment-naive individuals at initial presentation. However, their use is more problematic during follow-up in patients who are already on maintenance treatment. There is a need for a different system to guide COPD pharmacological management during follow-up. Recent large randomised controlled trials have provided important new information concerning the therapeutic effects of ICSs and long-acting bronchodilators on exacerbations. The new evidence regarding blood eosinophils and inhaled treatments, and the need to distinguish between initial and follow-up pharmacological management, led to changes in the GOLD pharmacological treatment recommendations. This article explains the evidence and rationale for the GOLD 2019 pharmacological treatment recommendations.read more
Citations
More filters
Journal ArticleDOI
Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis.
Rodrigo Torres-Castro,Luis Vasconcello-Castillo,Xavier Alsina-Restoy,Lilian Solis-Navarro,Felip Burgos,Homero Puppo,Jordi Vilaró +6 more
TL;DR: The objective was to determine the prevalence of restrictive pattern, obstructive pattern and altered diffusion in patients post-COVID-19 infection and to describe the different evaluations of respiratory function used with these patients.
Journal ArticleDOI
Gallic acid: Pharmacological activities and molecular mechanisms involved in inflammation-related diseases.
Jinrong Bai,Yunsen Zhang,Ce Tang,Ya Hou,Xiaopeng Ai,Xiaorui Chen,Yi Zhang,Xiaobo Wang,Xianli Meng +8 more
TL;DR: The results show that the anti-inflammatory mechanisms of GA mainly involved MAPK and NF-κB signaling pathways, which weakens the inflammatory response by reducing the release of inflammatory cytokines, chemokines, adhesion molecule and cell infiltration.
Journal ArticleDOI
COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis
Firoozeh V. Gerayeli,Stephen Milne,Stephen Milne,Chung Cheung,Xuan Li,Cheng Wei Tony Yang,Anthony Tam,Lauren H. Choi,Annie Bae,Don D. Sin +9 more
TL;DR: In this paper, a systematic review of COVID-19 clinical studies published between November 1st, 2019 and January 28th, 2021 (PROSPERO ID: CRD42020191491).
Journal ArticleDOI
Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico.
TL;DR: Age, sex and the most frequent comorbidities diabetes, obesity and hypertension were significantly associated to risk of death by COVID-19 (P<0.0001), and more attention to specific conditions might be considered during clinical admission.
References
More filters
Journal ArticleDOI
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.
Jørgen Vestbo,Suzanne S. Hurd,Alvar Agusti,Paul W. Jones,Claus Vogelmeier,Antonio Anzueto,Peter J. Barnes,Leonardo M. Fabbri,Fernando J. Martinez,Masaharu Nishimura,Robert A. Stockley,Don D. Sin,Roberto Rodriguez-Roisin +12 more
TL;DR: It is recommended that spirometry is required for the clinical diagnosis of COPD to avoid misdiagnosis and to ensure proper evaluation of severity of airflow limitation.
Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease
C Lenfant,N Khaltaev +1 more
Journal ArticleDOI
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
Claus Vogelmeier,Gerard J. Criner,Fernando J. Martinez,Antonio Anzueto,Peter J. Barnes,Jean Bourbeau,Bartolome R. Celli,Rongchang Chen,Marc Decramer,Leonardo M. Fabbri,Peter Frith,David M.G. Halpin,M. Victorina López Varela,Masaharu Nishimura,Nicolas Roche,Roberto Rodriguez-Roisin,Don D. Sin,Dave Singh,Robert Stockley,Jørgen Vestbo,Jadwiga A. Wedzicha,Alvar Agusti +21 more
TL;DR: The assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation, and the concept of deescalation of therapy is introduced in the treatment assessment scheme.
Journal ArticleDOI
Azithromycin for Prevention of Exacerbations of COPD
Richard K. Albert,Richard K. Albert,John E. Connett,William C. Bailey,Richard Casaburi,J. Allen D. Cooper,Gerard J. Criner,Jeffrey L. Curtis,Mark T. Dransfield,MeiLan K. Han,Stephen C. Lazarus,Barry J. Make,Nathaniel Marchetti,Fernando J. Martinez,Nancy E. Madinger,Charlene McEvoy,Dennis E. Niewoehner,Janos Porsasz,Connie S. Price,Connie S. Price,John J. Reilly,Paul D. Scanlon,Frank C. Sciurba,Steven M. Scharf,George R. Washko,Prescott G. Woodruff,Nicholas R. Anthonisen +26 more
TL;DR: Among selected subjects with COPD, azithromycin taken daily for 1 year, when added to usual treatment, decreased the frequency of exacerbations and improved quality of life but caused hearing decrements in a small percentage of subjects.
Journal ArticleDOI
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD
David A. Lipson,Frank Barnhart,Noushin Brealey,Jean Brooks,Gerard J. Criner,Nicola C. Day,Mark T. Dransfield,David M.G. Halpin,MeiLan K. Han,C. Elaine Jones,Sally Kilbride,Peter Lange,David A. Lomas,Fernando J. Martinez,Dave Singh,Maggie Tabberer,Robert A. Wise,Steven Pascoe +17 more
TL;DR: Triple therapy with fluticasone furoate, umeclidinium, and vilanterol resulted in a lower rate of moderate or severe COPD exacerbations than flutic asonefuroate–vilanterol or u meclid inium–vilAnterol in this population.
Related Papers (5)
Standardisation of spirometry
Martin R. Miller,John L. Hankinson,Vito Brusasco,Felip Burgos,Richard Casaburi,Allan L. Coates,Robert O. Crapo,Paul L. Enright,C.P.M. van der Grinten,P. Gustafsson,R. Jensen,D.C. Johnson,Neil R. MacIntyre,Roy T. McKay,Daniel Navajas,O. F. Pedersen,Riccardo Pellegrino,Giovanni Viegi,J. Wanger +18 more
Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary
Claus Vogelmeier,Gerard J. Criner,Fernando J. Martinez,Antonio Anzueto,Peter J. Barnes,Jean Bourbeau,Bartolome R. Celli,Rongchang Chen,Marc Decramer,Leonardo M. Fabbri,Peter Frith,David M.G. Halpin,M. Victorina López Varela,Masaharu Nishimura,Nicolas Roche,Roberto Rodriguez-Roisin,Don D. Sin,Dave Singh,Robert Stockley,Jørgen Vestbo,Jadwiga A. Wedzicha,Alvar Agusti +21 more